At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
Comparator: mometasone +2 moredrug
Likely dose
Comparator: mometasone 220 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma
In Brief
A Phase 2 clinical trial evaluating Comparator: mometasone, Comparator: montelukast, and 1 other intervention for Asthma. Completed, enrolled 134 participants.
Detailed Summary
This study assesses inhaled corticosteroid plus montelukast compared with inhaled corticosteroid therapy alone for treatment of patients with chronic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedApr 25, 2008
Enrollment StartMay 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.2 years ago
Interventions
Comparator: mometasonedrug
mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
Comparator: montelukastdrug
montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
Comparator: placebo (unspecified)drug
Placebo (Placebo once-daily, for approximately 2 weeks)